- Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: challenges and opportunities
European Journal of Preventive Cardiology · 2025
- GLP-1RA versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: An updated meta-analysis of randomized controlled trials
International Journal of Cardiology · 2025
- Heterogeneity of treatment effects of glucose-lowering drug classes for type 2 diabetes: LEGEND-T2DM network real-world evidence
Journal of Diabetes and its Complications · 2025
- Efficacy and safety of danuglipron ( <scp>PF</scp> ‐06882961) in adults with obesity: A randomized, placebo‐controlled, dose‐ranging phase 2b study
Diabetes Obesity and Metabolism · 2025
- Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide
Cardiovascular Diabetology · 2025
- Exploring the role of glucagon-like peptide-1 receptor agonists in critical illness: mechanisms, benefits, and clinical implications
Current Opinion in Critical Care · 2025
- Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
The Journal of Clinical Endocrinology & Metabolism · 2025
- The global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD): current status and future prospects
International Journal of Surgery · 2025
- Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care—a systematic review and network meta-analysis
Acta Diabetologica · 2025
- Glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and advanced CKD: kidney and cardiovascular outcomes in a real-world setting
Clinical Kidney Journal · 2025
- Heterogeneous treatment effects of GLP‐1RAs and SGLT2is on risk of Alzheimer's disease and related dementia in patients with type 2 diabetes: Insights from a real‐world target trial emulation
Alzheimer s & Dementia · 2025
- GLP-1 receptor agonists and pulmonary hypertension in diabetes: A promising therapeutic strategy
American Heart Journal Plus Cardiology Research and Practice · 2025
- Glucagon-like-peptide-1 (GLP-1) receptor agonist use and the risk of pulmonary aspiration in patients undergoing surgery
International Journal of Surgery · 2025
- Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
British Journal of Clinical Pharmacology · 2025
- Influence of glucagon-like peptide-1 receptor agonists on renal parameters: a meta-analysis of randomized controlled trials
BMC Endocrine Disorders · 2025
- Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Journal of the American Heart Association · 2025
- Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials
European Journal of Preventive Cardiology · 2025
- Pulmonary Artery Pressure Trajectories in Heart Failure Patients Treated with GLP-1 Receptor Agonists
ESC Heart Failure · 2025
- Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes
Cardiovascular Diabetology · 2025
- Availability of Cardioprotective Medications for Type 2 Diabetes in the Medicaid Program
Annals of Internal Medicine · 2025
- Impact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Current Opinion in Cardiology · 2025
- Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease
Diabetes Research and Clinical Practice · 2025
- Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: A propensity score-matched cohort study
International Journal of Cardiology · 2025
- Aspiration risk and strategic approach for patients receiving GLP-1 receptor agonists undergoing elective surgery
Current Medical Research and Opinion · 2025
- Recent Updates on the Renoprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists
Korean Journal of Medicine · 2025
- Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials
Diabetes Care · 2025
- A case series of incidents reported to webAIRS relating to glucagon-like peptide 1 agonist use
Anaesthesia and Intensive Care · 2025
- Adoption and Prescribing Practices of Sodium-Glucose Transport Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Agonists in Cardiology: A Cross-Sectional Study in Saudi Arabia
Cureus · 2025
- Anti-Inflammatory and Anti-Oxidative Effects of GLP1-RAs and SGLT2i: The Guiding Star Towards Cardiovascular Protection in Type 2 Diabetes
Immuno · 2025
- Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes
Cochrane Database of Systematic Reviews · 2025
- Comparison of the Effects of SGLT-2i versus GLP-1RA on Cardiovascular and Renal Outcomes in Patients with Type 2 Diabetes Mellitus based on Baseline Renal Function
Diabetes · 2025
- Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy · 2025
- Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary Disease Exacerbations in Patients With Type 2 Diabetes
JAMA Internal Medicine · 2025
- The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
Cardiovascular Diabetology · 2025
- Glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice
Cardiovascular Research · 2025
- Perioperative and periprocedural management of GLP-1 receptor-based agonists and SGLT2 inhibitors: narrative review and the STOP-GAP and STOP DKA-2 algorithms
Current Medical Research and Opinion · 2025
- Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials
American Journal of Kidney Diseases · 2025
- Factors Associated With Semaglutide Initiation Among Adults With Obesity
JAMA Network Open · 2025
- Unexpected cardiovascular risks of glucagon‐like peptide‐1 receptor agonist and aspirin co‐administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study
Diabetes Obesity and Metabolism · 2025
- Exploring the Potential Effect of GLP1R Agonism on Common Aging-Related Diseases via Glucose Reduction: A Mendelian Randomization Study
The Journals of Gerontology Series A · 2025
- Glucagon-Like Peptide-1 Receptor Agonists in the Peri-Operative Period
British Journal of Hospital Medicine · 2025
- Long-term prognostic impact of glucagon-like peptide-1 receptor agonist before ST-segment elevation myocardial infarction in patients with type 2 diabetes: a nationwide cohort study
Cardiovascular Diabetology · 2025
- The Role of GLP-1 Receptor Agonists in Managing Cancer Therapy-Related Cardiac Dysfunction
2025
- SGLT2 Inhibitor and GLP‐1 Receptor Agonist Prescriptions in Newly Diagnosed Type 2 Diabetes Patients With Cardiorenal Risks: A Cross‐Sectional Study
Journal of Diabetes Research · 2025
- Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis
Biomolecules · 2024
- Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials
Diabetes Obesity and Metabolism · 2024
- Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway
British Journal of Pharmacology · 2024
- Identifying predictors of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist use in hospital among adults with diabetes
Journal of Diabetes and its Complications · 2024
- Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference
American Journal of Physiology-Heart and Circulatory Physiology · 2024
- Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease
Nature Communications · 2024